Evidence map›Paper›PMID 42484650›Full record

ArticleJournal of neurology2026

Effect of continuous subcutaneous foslevodopa/foscarbidopa infusion on gait in advanced Parkinson's disease: a real-world wearable-based study.

Kristi Meksi, Clara Simonetta, Jacopo Campone, Valerio Ferrari, Matteo Antonucci, Matteo Conti, Tommaso Schirinzi, Diego Centonze, Francesca Avvento, Alessandro Stefani and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kristi MeksiNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Clara SimonettaNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Jacopo CamponeNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Valerio FerrariNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Matteo AntonucciDepartment of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Matteo ContiNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Tommaso SchirinziNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Diego CentonzeNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Francesca AvventoNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
Alessandro StefaniNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy. stefani@uniroma2.it.
Mariangela PierantozziNeurology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.

Funding

Ministero della Salute PNNR-MCNT1-2023- 12378408
6 · The paper itself

Abstract

backgroundIn patients with advanced Parkinson's disease (PD), spatiotemporal gait parameters and freezing of gait (FoG) show a variable responsiveness to levodopa, with FoG often exacerbated by motor fluctuations. Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion effectively reduces motor fluctuations; however, its effects on gait remain incompletely explored.

objectivesTo provide an objective, wearable-based assessment of FoG and gait parameters during LDp/CDp infusion in patients with PD, and to investigate their association with motor fluctuations and clinical outcomes.

methodsPD patients were evaluated at baseline (T0), after 6 (T1) and 12 months (T2) of LDp/CDp therapy. Real-world monitoring was performed using a wearable sensor (STAT-ON) for five consecutive days at each timepoint. Wearable-derived outcomes included FoG/h, gait parameters (gait speed, step length, cadence, stride fluidity) and motor-state distribution (OFF-time, ON-time, dyskinesia). Clinical assessments included MDS-UPDRS Part III-IV, new Freezing of Gait Questionnaire (NFOG-Q) and PDQ-39.

resultsFoG/h, stride fluidity, step length improved significantly over time (p = 0.017, p = 0.004, p = 0.002, respectively), alongside the reduction in OFF time (p = 0.043) and dyskinesia (p = 0.021). MDS-UPDRS Part IV, NFOG-Q, and PDQ-39 scores improved significantly in parallel. OFF-time reduction was associated with reduced FoG burden (ρ = 0.657, p = 0.011) and increased stride fluidity (ρ = - 0.741, p = 0.002). Post-hoc analyses indicated that improvements were evident at T1 and maintained at T2. LEDD remained unchanged.

conclusionsLDp/CDp infusion is effective in improving FoG and selected gait parameters in PD, reflecting stabilization of motor fluctuations without increased dopaminergic exposure.

Indexed as

Antiparkinson AgentsCarbidopaGait Disorders, NeurologicLevodopaParkinson DiseaseWearable Electronic DevicesAgedDrug CombinationsFemaleHumansInfusions, SubcutaneousMaleMiddle AgedAntiparkinson AgentsCarbidopacarbidopa, levodopa drug combinationDrug CombinationsLevodopaFoslevodopa/foscarbidopaFreezing of gaitMotor fluctuationsParkinson’s diseaseWearable sensors

Identifiers

PMID42484650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.